PLA2G2E
Group IIE secretory phospholipase A2
Also known as: PA2GE_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NZK7
- Gene
- PLA2G2E
- Ensembl
- ENSG00000188784
- Chromosome
- 1
- Canonical length
- 142 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted secreted proteins, RAS pathway related proteins
- Secretome location
- Secreted - unknown location
OverviewNCBI Gene
Enables calcium ion binding activity and calcium-dependent phospholipase A2 activity. Predicted to be involved in phosphatidylcholine metabolic process and phosphatidylglycerol metabolic process. Predicted to act upstream of or within low-density lipoprotein particle remodeling. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
142 residues, UniProt reviewed canonical sequence.
>Q9NZK7|PLA2G2E
1 MKSPHVLVFL CLLVALVTGN LVQFGVMIEK MTGKSALQYN DYGCYCGIGG SHWPVDQTDW
61 CCHAHDCCYG RLEKLGCEPK LEKYLFSVSE RGIFCAGRTT CQRLTCECDK RAALCFRRNL
121 GTYNRKYAHY PNKLCTGPTP PCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PLA2G2E can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 2.3 nTPM
Expression across tissuesHPA
Tissue
- tonsil: 2.3 nTPM
- skin: 0.4 nTPM
- parathyroid gland: 0.1 nTPM
- small intestine: 0.1 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
Single-cell type
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
- alveolar cells type 2: 0 nCPM
- astrocytes: 0 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 0.7 nTPM
- hippocampal formation: 0.4 nTPM
- white matter: 0.4 nTPM
- amygdala: 0.3 nTPM
- cerebellum: 0.2 nTPM
- basal ganglia: 0.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.74
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.29
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- arachidonate secretion
- inflammatory response
- lipid catabolic process
- low-density lipoprotein particle remodeling
- phosphatidylcholine metabolic process
- phosphatidylglycerol metabolic process
- phospholipid metabolic process
Molecular functions
- calcium ion binding
- calcium-dependent phospholipase A2 activity
- phospholipase A2 activity
- phospholipid binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PLA2G2E as an antibody target. Whether an autoantibody or antibody against PLA2G2E could matter depends on whether native PLA2G2E is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PLA2G2E is annotated as secreted, so native PLA2G2E circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PLA2G2E as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...